Almitas Capital LLC acquired a new position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 254,655 shares of the company's stock, valued at approximately $751,000. Almitas Capital LLC owned about 0.91% of Vistagen Therapeutics as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in shares of Vistagen Therapeutics by 4,826,425.0% in the 4th quarter. JPMorgan Chase & Co. now owns 772,244 shares of the company's stock valued at $2,278,000 after acquiring an additional 772,228 shares in the last quarter. Nantahala Capital Management LLC boosted its holdings in Vistagen Therapeutics by 30.6% in the fourth quarter. Nantahala Capital Management LLC now owns 1,981,980 shares of the company's stock worth $5,847,000 after acquiring an additional 464,284 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Vistagen Therapeutics in the fourth quarter valued at approximately $123,000. AdvisorShares Investments LLC raised its position in shares of Vistagen Therapeutics by 47.3% during the fourth quarter. AdvisorShares Investments LLC now owns 99,810 shares of the company's stock worth $294,000 after purchasing an additional 32,030 shares during the period. Finally, Prosperity Wealth Management Inc. bought a new position in Vistagen Therapeutics in the 4th quarter valued at about $86,000. Institutional investors and hedge funds own 78.39% of the company's stock.
Vistagen Therapeutics Stock Performance
VTGN stock traded up $0.03 during mid-day trading on Wednesday, hitting $2.18. The company had a trading volume of 47,526 shares, compared to its average volume of 167,945. Vistagen Therapeutics, Inc. has a 12 month low of $1.90 and a 12 month high of $4.75. The stock's fifty day moving average price is $2.42 and its two-hundred day moving average price is $2.69. The firm has a market cap of $62.89 million, a PE ratio of -1.47 and a beta of 0.67.
Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.02. The company had revenue of $230 billion during the quarter, compared to analyst estimates of $0.18 million. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%. Equities analysts anticipate that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current year.
Vistagen Therapeutics Company Profile
(
Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Further Reading
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
